A Study of Evorpacept (ALX148) in Patients with Advanced HER2+ Gastric Cancer (ASPEN-06)

Description

A Phase 2/3 Study of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma.

Conditions

Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma

Talk to us

Study Overview

On this page

Study Details

Study overview

A Phase 2/3 Study of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma.

A Phase 2/3 Study of Evorpacept (ALX148) in Patients with Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06)

A Study of Evorpacept (ALX148) in Patients with Advanced HER2+ Gastric Cancer (ASPEN-06)

Condition
Gastric Cancer
Intervention / Treatment

-

Contacts and Locations

Anaheim

The Oncology Institute of Hope & Innovation, Anaheim, California, United States, 92801

Los Angeles

University of California Los Angeles, Los Angeles, California, United States, 90095

Nashville

Vanderbilt University Medical Center, Nashville, Tennessee, United States, 37232

Fairfax

NEXT Virginia, Fairfax, Virginia, United States, 22031

Seattle

Fred Hutchinson Cancer Center, Seattle, Washington, United States, 98109

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * HER2-overexpressing advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on or after a prior HER2-directed agent and fluoropyrimidine- or platinum-containing chemotherapy (2nd-line or 3rd-line)
  • * Adequate Bone Marrow Function.
  • * Adequate Renal \& Liver Function.
  • * Adequate Performance Status
  • * Patients with known symptomatic CNS metastases or leptomeningeal disease requiring steroids.
  • * Prior treatment with any anti-CD47 or anti-SIRPα agent.
  • * Prior treatment with ramucirumab.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

ALX Oncology Inc.,

Study Record Dates

2028-08